Hims & Hers Valuation, Funding & Investors

Hims & Hers is valued at $1.1B as of January 2019.

Last Hims & Hers valuation

$1.1B

Series C · Jan 2019

Last Hims & Hers funding round

$100M

Series C · Jan 2019

Cumulative funding Hims & Hers raised

$157M

across 3 funding rounds

Key investors in Hims & Hers

  • Forerunner
  • Maverick Capital
  • Founders Fund
  • SV Angel
  • Redpoint
  • Thrive Capital

Hims & Hers Overview

About Hims & Hers

Hims & Hers is a San Francisco-headquartered telehealth platform connecting patients with licensed providers for treatments in hair loss, erectile dysfunction, mental health, dermatology, and weight management. Founded in 2017 and public on NYSE since 2021, it serves 1.5 million subscribers through its proprietary electronic health record system. Partnerships with Ochsner Health, Mount Sinai, and Privia Health enable hybrid virtual and in-person care, with Hers brand launched in 2018 expanding women's health options like skincare and birth control.


Founded

2017

HQ

United StatesSan Francisco, CA

Website

hims.com

Status

Privately held

Customer focus

B2C

Revenue model

Subscription

Valuation

$1.1B (Jan 2019)

Hims & Hers Valuation

Hims & Hers is currently valued at $1.1B, based on its Series C in January 2019. Read the announcement ↗

The $100M round included Redpoint, SV Angel, 8VC, Kyle Widrick, Forerunner and 6 other investors.

Hims & Hers' valuation has grown 3.1x from $350M at its Series B in June 2018 to $1.1B in January 2019, across 2 priced rounds.

Hims & Hers valuation by funding round

Hims & Hers valuation by funding round
DateStageValuation
Jan 2019Series C$1.1B
Jun 2018Series B$350M

Hims & Hers Funding History

Hims & Hers has raised a total of $157M across 3 funding rounds.

Hims & Hers' first fundraising round was a $7M Series A in November 2017. The most recent completed round was a $100M Series C in January 2019.

Hims & Hers funding rounds

Hims & Hers funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jan 2019Series CRedpoint; SV Angel; 8VC; Kyle Widrick; Forerunner; Maverick Capital; Cherubic Ventures; Founders Fund; Counterpart Advisors; DCM Ventures; Russell Cook$100M$1.1BHims & Hers, a telehealth platform offering men's and women's wellness products including treatments for hair loss, sexual health, skin care, erectile dysfunction, birth control, and hypoactive sexual desire disorder, raised $100 million in a Series C funding round in January 2019. The round valued the company at a $1 billion pre-money valuation, achieving unicorn status just over a year after launch, with post-money reaching $1.1 billion after adding the round size. Investors included Forerunner Ventures, Founders Fund, Redpoint Ventures, SV Angel, 8VC, Maverick Capital, and others matching the query's list such as DCM Ventures, with participation from a growth-stage lead investor described as a 'super big fund' not previously in Hims. This funding brought total capital raised to nearly $200 million across seven rounds, following a $50 million Series B at $350 million pre-money in June 2018. The company had launched Hers, its women's wellness brand, expanding beyond men's products amid competitive negotiations where some investors balked at the valuation, but Hims secured the deal with ample cash reserves from prior rounds led by IVP. Funds supported ongoing growth in direct-to-consumer sales and product expansion. The round positioned Hims as a leader in digital health personal care, competing in hair, skin, and sexual wellness sectors alongside startups like Madison Reed and Billie.
Jun 2018Series BIVP (lead); Redpoint; Forerunner; Maverick Capital; Founders Fund; Thrive Capital; 7GC & Co$50M$350MHims & Hers, originally launched as Hims in 2017, is a San Francisco-based direct-to-consumer telehealth platform specializing in men's wellness products such as hair loss treatments, erectile dysfunction medications, and skin care, later expanding to women's health under the Hers brand. The company raised a $50 million Series B round in June 2018 led by IVP, with participation from Forerunner Ventures, Redpoint Ventures, Founders Fund, Thrive Capital, and Maverick Ventures, bringing total funding to $97 million at that point. This Series B followed an earlier investment from IVP in January 2018 and supported Hims' ambitions to apply a direct-to-consumer model to healthcare for chronic conditions, amid rapid early growth. The round positioned Hims among personal care startups securing significant venture capital, alongside peers like Madison Reed and Billie. Subsequently, Hims raised a $100 million Series C round, reportedly valuing the company at $1 billion, with backers including 7GC & Co (likely 7 Global Capital), Founders Fund, and others, bringing total funding closer to $200 million by late 2018 or early 2019. IVP highlighted the company's innovative approach in a retrospective, noting its public launch via SPAC in 2021 at $1.6 billion enterprise value. Later data showed $27 million revenue in 2018 per internal figures shared during the SPAC.
Nov 2017Series AThrive Capital (lead); Align Ventures; SV Angel; Forerunner; Maverick Capital; Oxeon Partners; UpHonest Capital$7M--

Who has invested in Hims & Hers?

17 investors have backed Hims & Hers across its funding rounds, including Forerunner, Maverick Capital, Founders Fund, SV Angel, Redpoint and Thrive Capital.

Lead investors include IVP and Thrive Capital.


Hims & Hers Investors

Investors in Hims & Hers by funding rounds participated
InvestorHQRoundsRoleFirst check
ForerunnerUnited StatesSan Francisco, CA3ParticipantNov 2017
Maverick CapitalUnited StatesDallas, TX3ParticipantNov 2017
RedpointUnited StatesSan Francisco, CA2ParticipantJun 2018
SV AngelUnited StatesSan Francisco, CA2ParticipantNov 2017
Founders FundUnited StatesSan Francisco, CA2ParticipantJun 2018
Thrive CapitalUnited StatesNew York City, NY2LeadNov 2017
Align VenturesUnited StatesNew York City, NY1ParticipantNov 2017
IVPUnited StatesMenlo Park, CA1LeadJun 2018
8VCUnited StatesAustin, TX1ParticipantJan 2019
Kyle WidrickUnited StatesNew York City, NY1ParticipantJan 2019
Cherubic VenturesTaiwanTaipei1ParticipantJan 2019
Oxeon PartnersUnited StatesNew York City, NY1ParticipantNov 2017
UpHonest CapitalUnited StatesSan Francisco, CA1ParticipantNov 2017

This data is available for Pro users. Sign up to see all 17 Hims & Hers investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Hims & Hers

Hims & Hers has acquired 7 companies to date.

Last acquisition by Hims & Hers was on February 19th 2026. Hims & Hers acquired Eucalyptus for $1.1B.


Latest Acquisitions by Hims & Hers

Eucalyptus
Livewell
YourBio Health
ZAVA
Description
Eucalyptus is a Sydney digital-health company founded in 2019 by Tim Doyle, Charlie Gearside, Alexey Mitko and Benny Kleist. It runs direct-to-consumer telehealth brands including Pilot for men's health, Juniper for women's weight loss and menopause, Kin for fertility and Software for prescription skincare, and Athletic Ventures describes it as a high-touch, high-quality digital healthcare business with five brands that also include Compound. Blackbird said the business differentiates through customer experience and launches distinct brands for underserved patient groups on shared infrastructure. Its cap table included Blackbird, Airtree, Woolworths' venture fund W23, OneVentures, Athletic Ventures and Mary Meeker's BOND Capital. In February 2026 Hims & Hers Health agreed to buy the company for US$1.15 billion, with US$240 million upfront and deferred payments over 18 months plus an earnout through early 2029, when its revenue run-rate exceeded US$450 million.
Livewell is a Montreal-based digital health company specializing in weight loss therapies through virtual consultations and personalized programs.
YourBio Health is a Medford-based biotech company developing the Seventh Sense On Vivo platform for simplified blood sampling. Its Touch Activated Phlebotomy technology uses microneedle patches for painless, at-home diagnostic testing compatible with assays for glucose, cholesterol, and infectious diseases. The Boston-area firm advances point-of-care diagnostics, partnering with labs to improve patient access and healthcare delivery.
ZAVA is a London-headquartered telehealth provider offering online consultations with general practitioners across the UK, Germany, France, Ireland, and Scandinavia. Patients submit medical questionnaires for conditions like erectile dysfunction, contraception, and hair loss, receiving prescriptions and discreet deliveries without in-person appointments. Follow-up doctor support remains available post-treatment.
HQ CountryAustraliaCanadaUnited StatesUnited Kingdom
HQ City
Sydney
-
Boston, MA
London
Deal Date19 Feb 20264 Dec 20253 Dec 20253 Jun 2025
Valuation$1.1Bundisclosedundisclosed$450M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Hims & Hers acquisitions and their M&A valuation multiples.

Start Free Trial

Hims & Hers Competitors

Hims & Hers competitors include listed companies like Kooth and Nyxoah, and private ones like Forward, Midi Health, SheMed and Calibrate.

Public and private companies comparable to Hims & Hers
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
ForwardUnited StatesSan Francisco, CAPrivate--$1B-
Midi HealthUnited StatesLos Angeles, CAPrivate$150M-$1B6.7x
SheMedUnited KingdomUnited KingdomPrivate--$1B-
CalibrateUnited StatesNew York City, NYPrivate$21M-$1.3B61.9x
KoothUnited KingdomUnited KingdomPublicly listed$85M$13M$92M0.7x
NyxoahBelgiumBelgiumPublicly listed$11M($95M)$90M1.1x

Hims & Hers Public Comps

Hims & Hers is still privately-owned, but its public comps include GoodRx, Helus Pharma, Ping An Healthcare, Sphere, Alignment Healthcare, JMDC, Teladoc, Compass Pathways, Medley Inc. and Guiyang Longmaster.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
GoodRx$797M$173M1.8x1.8x8.3x5.7x
Helus Pharma-($153M)--(4.0x)(3.4x)
Ping An Healthcare$822M$52M0.7x0.7x10.4x14.6x
Sphere$72M$7M12.6x4.6x137.8x91.4x
Alignment Healthcare$3.9B$45M0.3x0.2x24.5x9.7x
JMDC$320M$87M5.1x4.6x18.9x17.9x
Teladoc$2.5B$124M0.7x0.7x14.0x6.0x
Compass Pathways-($293M)--(4.2x)(6.0x)

This data is available for Pro users. Sign up to see all Hims & Hers competitors and their valuation data.

Start Free Trial

Common questions about Hims & Hers

When was Hims & Hers founded?Hims & Hers was founded in 2017.
Where is Hims & Hers headquartered?Hims & Hers is headquartered in San Francisco, CA, United States.
Is Hims & Hers publicly listed?No, Hims & Hers is a private, VC-backed company.
What is Hims & Hers' valuation?Hims & Hers was last valued at $1.1B in its Series C in January 2019.
How much funding has Hims & Hers raised?Hims & Hers has raised $157M across 3 funding rounds.
What was Hims & Hers' last funding round?Hims & Hers' last funding round was a $100M Series C in January 2019.
Who are Hims & Hers' investors?Hims & Hers' investors include Forerunner, Maverick Capital, Redpoint, SV Angel, Founders Fund, Thrive Capital, Align Ventures, IVP, 8VC, Kyle Widrick and 7 others.
Which companies are comparable to Hims & Hers?Companies comparable to Hims & Hers include Forward, Midi Health, SheMed, Calibrate, Kooth and Nyxoah.
How many companies has Hims & Hers acquired?Hims & Hers has acquired 7 companies, including Eucalyptus, Livewell, YourBio Health, ZAVA and Trybe Labs.
What was the largest acquisition by Hims & Hers?The $1.1B acquisition of Eucalyptus in February 2026 is the largest acquisition Hims & Hers has made to date.

See companies similar to Hims & Hers

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial